This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q62105033
rdf:type
wikibase:Item
schema:description
клінічне випробування ensayu clínicu klinisch onderzoek clinical trial
rdfs:label
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
skos:prefLabel
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
schema:name
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
p:P1476
wds:Q62105033-3C51E35D-E9FA-4C1E-8CCD-5F8FE2680544
wdt:P1476
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
p:P31
wds:Q62105033-469FD1E0-52DB-4A98-96B8-A751921774EF
wdt:P31
wd:Q30612
p:P580
wds:Q62105033-6B32815E-D50F-4089-97E1-E4361125F3D4
wdt:P580
2004-11-01T00:00:00Z
p:P17
wds:Q62105033-5AA87BDE-AA5E-43A0-9325-8E16F24E65FE
wdt:P17
wd:Q142
p:P6153
wds:Q62105033-A71E2430-5F3D-490E-9F41-28A3420FD99D wds:Q62105033-BB556B71-A376-46D5-BBD6-9D9B4583D7E6 wds:Q62105033-445D31CE-8D2F-49EE-BD37-7B5832B5FB26 wds:Q62105033-2A6B8213-CB50-4CDA-9715-853471B013CF wds:Q62105033-429E029D-80BA-4779-B8AC-676349B29A96 wds:Q62105033-6126C7B1-6A57-484B-8CFD-B5679347ACD5 wds:Q62105033-7663709B-1A17-449D-9C19-E96E29AF935B wds:Q62105033-7C701533-EA42-4CE2-9FB3-C6F675C66761 wds:Q62105033-565D4B4D-5B15-4F96-BFD3-428E1BEE282F wds:Q62105033-10095CF6-EE26-40BC-B1B5-350E8957B77A wds:Q62105033-20106AA0-7F22-4D60-8453-605F01C3DE4F wds:Q62105033-CE11ADCC-A553-4FEE-A7B2-3726D71D1C26 wds:Q62105033-A31921AE-7EC0-4906-8CE0-8036B9A00C69
wdt:P6153
wd:Q89798279 wd:Q50037243 wd:Q3151727 wd:Q3145366 wd:Q2945675 wd:Q2944826 wd:Q16508267 wd:Q30269748 wd:Q2944832 wd:Q30296137 wd:Q266227 wd:Q3145138 wd:Q3145128
p:P4844
wds:Q62105033-47CE59AE-EDFC-4B5D-9EF6-FDE6F3900A3A wds:Q62105033-04B8FD9D-93E3-4A47-9FFD-23000848F5AE wds:Q62105033-FF2C42BE-7B92-4C11-B7D3-02E8D28ED740 wds:Q62105033-EFF17877-2695-4C51-9FA2-29227747B115 wds:Q62105033-2803F40F-7F7C-4CCA-8796-D1D7B4739455
wdt:P4844
wd:Q414143 wd:Q412197 wd:Q422327 wd:Q238512 wd:Q192464
p:P1132
wds:Q62105033-60C15962-52FF-4798-8892-3B7C86BAA8A8
wdt:P1132
348
p:P8363
wds:Q62105033-42FEC152-1C17-47D6-933C-7B50DB52A03A
wdt:P8363
wd:Q78089383
p:P3098
wds:Q62105033-49F3621B-8021-42EE-9FF1-FAB2ADACC03D
wdt:P3098
NCT00112658
p:P6099
wds:Q62105033-F1063E21-9FB1-4D76-81DA-CC48EA44347A wds:Q62105033-85338541-4C8F-4C32-9E06-B05FEB944A27
wdt:P6099
wd:Q42824440 wd:Q42824827
p:P8005
wds:Q62105033-02C4BD9A-1F00-4388-82F2-FB672F938BA0
wdt:P8005
wd:Q76651279